Phospholipid Nanosomes

Aphios Corporation, 3-E Gill Street, Woburn, MA 01801, USA.
Current Drug Delivery (Impact Factor: 1.48). 11/2005; 2(4):329-40. DOI: 10.2174/156720105774370195
Source: PubMed


Phospholipid nanosomes are small, uniform liposomes manufactured utilizing supercritical fluid technologies. Supercritical fluids are first used to solvate phospholipid raw materials, and then decompressed to form phospholipid nanosomes that can encapsulate hydrophilic molecules such as proteins and nucleic acids. Hydrophobic therapeutics are co-solvated with phospholipid raw materials in supercritical fluids that, when decompressed, form phospholipid nanosomes encapsulating these drugs in their lipid bilayers. Mathematical modeling and semi-empirical experiments indicate that the size and character of phospholipid nanosomes depend on the several process parameters and material properties including the size and design of decompression nozzle, bubble size, pressure and the rate of decompression, interfacial forces, charge distribution and the nature of compound being encapsulated. Examples are presented for the encapsulation of a protein and hydrophobic drugs. In vitro and in vivo data on breast cancer cells and xenografts in nude mice indicate that paclitaxel nanosomes are less toxic and much more effective than paclitaxel in Cremophor EL (Taxol). Camptothecin nanosomes demonstrate that the normally very water-insoluble camptothecin can be formulated in a biocompatible aqueous medium while retaining in vivo efficacy against lymphoma xenografts in nude mice. In vitro data for betulinic acid nanosomes demonstrate enhanced efficacy against HIV-1 (EC50 of 1.01 microg/ml versus 6.72 microg/ml for neat betulinic acid). Phospholipid nanosomes may find utility in the enhanced delivery of hydrophilic drugs such as recombinant proteins and nucleic acid as well as hydrophobic anticancer and anti-HIV drugs.

187 Reads
  • Source
    • "6. Depressurization of an Expanded Solution into Aqueous Media (DESAM) [1] [28]. 7. Depressurization of an Expanded Liquid Organic Solution (DELOS) [29] [30]. 8. SuperFluids (SFS-CFN) [31]. 9. Supercritical Liposome Method [32]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Formation of nano-carriers such as vesicles and micelles using dense gas processing has been under extensive research for decades. Several dense gas processes have been developed to produce nano-carriers, most of them being batch processes. In the present study, a novel continuous dense gas, known as nano-carrier by a continuous dense gas (NADEG) process was developed as an evolution of a dense gas batch process known as the Depressurization of an Expanded Solution into Aqueous Media (DESAM) process. Transforming a batch process into a continuous process is a main aspect of process intensification. The NADEG process developed in this work enhances the production output of the batch process while producing nano-carriers free of harmful residual organic solvent. The NADEG process is a one-step process for the production of nano-carriers with lower size and higher encapsulation efficiency than the nano-carriers produced by other batch processes. Encapsulation efficiencies as high as 15% were achieved using liposomes to encapsulate a model hydrophilic compound (isoniazid) while encapsulation efficiencies of 10% were achieved in polymersomes for the same model compound. Full Article:
    Chemical Engineering Journal 04/2015; 266. DOI:10.1016/j.cej.2014.12.072 · 4.32 Impact Factor
  • Source
    • "However, none of these approaches has been satisfactory enough to be introduced to the clinical practice, mostly because of the lack of biocompatibility to meet the requirements of intravenous preparations. Of these, the use of lipidic carriers in the form of emulsions (Nornoo, 2008) nanoscale lipocores and liposomes (Terwogt, et al., 1997; Nuijen, et al. 2001; Singla et al. 2002; Castor, 2005; Safavy, 2008) for increasing the drug solubility are one of the most promising, but still awaiting further characterization. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to study the basic features of Taxol recognition with phospholipids by applying the thermodynamic and spectroscopic measurements. The obtained information could be used further for deductions on its precise cellular and pharmacological mechanisms of action, on improvements of its solubility properties by phospholipids, as well as for designing the novel lipidic carriers for drug delivery.
    Brazilian Archives of Biology and Technology 12/2010; 53(6):1351-1358. DOI:10.1590/S1516-89132010000600011 · 0.55 Impact Factor
  • Source
    • "The most known viral vehicles having been effectively employed as gene transfer vectors in vitro include the vaccinia viruses [3], herpes simplex viruses[4], adenoviruses[5], influenza viruses [6], lentiviruses [7] retroviruses [8], and adeno-associated viruses. Non-viral vehicles include polymers (condensing and non-condensing ones)[9], bacterial spores[10], proteosomes [11], exosomes [12], liposomes [13], virosomes [14], superfluids [15], nanoparticle-based nanobeads [16], virus-liked particles [17] and bacteriophages [18]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Lambda phages have considerable potential as gene delivery vehicles due to their genetic tractability, low cost, safety and physical characteristics in comparison to other nanocarriers and gene porters. Little is known concerning lambda phage-mediated gene transfer and expression in mammalian hosts. We therefore performed experiments to evaluate lambda-ZAP bacteriophage-mediated gene transfer and expression in vitro. For this purpose, we constructed recombinant lambda-phage nanobioparticles containing a mammalian expression cassette encoding enhanced green fluorescent protein (EGFP) and E7 gene of human papillomavirus type 16 (lambda-HPV-16 E7) using Lambda ZAP- CMV XR vector. Four cell lines (COS-7, CHO, TC-1 and HEK-239) were transduced with the nanobioparticles. We also characterized the therapeutic anti-tumor effects of the recombinant lambda-HPV-16 E7 phage in C57BL/6 tumor mice model as a cancer vaccine. Obtained results showed that delivery and expression of these genes in fibroblastic cells (COS-7 and CHO) are more efficient than epithelial cells (TC-1 and HEK-239) using these nanobioparticles. Despite the same phage M.O.I entry, the internalizing titers of COS-7 and CHO cells were more than TC-1 and HEK-293 cells, respectively. Mice vaccinated with lambda-HPV-16 E7 are able to generate potent therapeutic antitumor effects against challenge with E7- expressing tumor cell line, TC-1 compared to group treated with the wild phage. The results demonstrated that the recombinant lambda-phages, due to their capabilities in transducing mammalian cells, can also be considered in design and construction of novel and safe phage-based nanomedicines.
    Genetic Vaccines and Therapy 05/2010; 8(1):3. DOI:10.1186/1479-0556-8-3 · 2.10 Impact Factor
Show more


187 Reads
Available from